Dendreon Corp. (Nasdaq: DNDN) was rated new Buy by R.F. Lafferty with a price target of $8. Lafferty noted low expectations for Provenge, a drug analysts have strong conviction will have a place in treatment of prostate cancer. Lafferty thinks the company is positioned to turn profitable. Against this backdrop, analysts view risk/reward as positive.

For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.